Company Analysis

Immix Biopharma, Inc. (IMMX)

Nasdaq: IMMX · Pharmaceutical Preparations · Los Angeles, CA · filing with the SEC since 2021
Grade6.1
◀ Past 4.8● Present 6.8▶ Future 6.3
7 est.

Filings

150 filings since 2017 beside 96 insider forms · Non-accelerated filer and smaller reporting company and emerging growth company · read from EDGAR on Nov 13, 2026
Due nextNon-accelerated filer and smaller reporting company and emerging growth company
10-K Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends. by Mar 31, 2027
10-Q Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end. by May 15, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 43 days after the quarter ended. The proxy statement was last filed Apr 6, 2026.

Filings a yearinsider forms included
393346443945
202120222023202420252026

2026 counts to Nov 13, 2026.

Officer or director change (8-K item 5.02): 2 times in the last 36 months, the newest Sep 8, 2025.Auditor change (8-K item 4.01): 1 time in the last 36 months, the newest Jul 22, 2024.SEC letters: 3 in the last 36 months, the newest Jan 16, 2026.
Insider forms 96

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Nov 12, 2026 8-K items 2.02, 9.01 Results released · Current report
Nov 12, 2026 10-Q Quarterly report Sep 30, 2026
Oct 27, 2026 SCHEDULE 13G Large holder notice
Sep 30, 2026 8-K items 8.01, 9.01 Other event · Current report Sep 29, 2026
Sep 29, 2026 FWP Offering communication
Sep 29, 2026 424B5 Shelf offering
Sep 29, 2026 8-K items 7.01, 8.01, 9.01 Investor disclosure (Regulation FD); Other event · Current report
Aug 14, 2026 SCHEDULE 13G Large holder notice
Aug 13, 2026 SCHEDULE 13G/A Large holder update, amended
Aug 7, 2026 10-Q Quarterly report Jun 30, 2026
Jul 20, 2026 8-K item 8.01 Other event · Current report
Jun 5, 2026 SCHEDULE 13G/A Large holder update, amended
May 29, 2026 8-K item 5.07 Shareholder vote · Current report May 22, 2026
May 21, 2026 8-K items 8.01, 9.01 Other event · Current report
May 21, 2026 424B5 Shelf offering
May 21, 2026 FWP Offering communication
May 21, 2026 8-K items 7.01, 8.01, 9.01 Investor disclosure (Regulation FD); Other event · Current report
May 15, 2026 SCHEDULE 13G/A Large holder update, amended
May 7, 2026 10-Q Quarterly report Mar 31, 2026
May 4, 2026 SCHEDULE 13G/A Large holder update, amended
Apr 6, 2026 ARS Annual report to shareholders Dec 31, 2025
Apr 6, 2026 DEFA14A Extra proxy material
Apr 6, 2026 DEF 14A Proxy statement
Mar 30, 2026 8-K items 7.01, 8.01, 9.01 Investor disclosure (Regulation FD); Other event · Current report
Mar 27, 2026 10-K/A Annual report, amended Dec 31, 2025
Mar 25, 2026 S-8 Employee stock plan registration
Mar 25, 2026 8-K items 1.01, 9.01 Major agreement signed · Current report
Mar 25, 2026 424B5 Shelf offering
Mar 25, 2026 10-K Annual report Dec 31, 2025
Mar 20, 2026 SCHEDULE 13G Large holder notice
Feb 17, 2026 SCHEDULE 13G Large holder notice
Feb 17, 2026 SCHEDULE 13G Large holder notice
Jan 22, 2026 EFFECT Registration effective
Jan 16, 2026 CORRESP Reply to the SEC
Jan 16, 2026 UPLOAD SEC comment letter
Jan 9, 2026 S-3 Shelf registration
Dec 8, 2025 8-K items 1.01, 9.01 Major agreement signed · Current report Dec 7, 2025
Dec 8, 2025 424B5 Shelf offering
Dec 8, 2025 8-K items 7.01, 8.01, 9.01 Investor disclosure (Regulation FD); Other event · Current report Dec 7, 2025
Dec 8, 2025 FWP Offering communication
40 of 150 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton IMMX · research, not advice